EUVIMEDEUVIMED entdecken
Open Access

Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment

Margaret Lowenstein, M Holliday Davis, Selena Suhail-Sindhu, Gary McMurtrie, David Grande, Julia Hinckley, Shoshana V Aronowitz

JAMA Network Open · 16.06.2026 · 9 (6) · e2618878

DOI: 10.1001/jamanetworkopen.2026.18878 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 16.06.2026. Verfasst von Margaret Lowenstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Opiate Substitution Treatment, Practice Patterns, Physicians'. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Treatment of opioid use disorder (OUD) with buprenorphine reduces overdose and all-cause mortality, yet access and retention remain limited. Much of the literature describing barriers to buprenorphine access and retention has focused on practitioner-level or patient-level barriers, but less is known about how potential policy and payment levers may influence prescribing behaviors and treatment practices from the practitioner perspective.

Objective

To explore perspectives among OUD treatment program clinicians and staff about how broader policy and payment structures influence adoption of buprenorphine treatment and low-barrier care practices that promote access and retention. Design, Setting, and Participants In this qualitative study, semistructured interviews were conducted from December 2022 to July 2023. Participants included clinicians and staff from a range of outpatient treatment programs providing buprenorphine in Philadelphia, Pennsylvania. Main Outcomes and Measures Interviews examined prescribing practices and the influence of policy, payment structures, and regulatory requirements on clinical care. Transcripts were analyzed using thematic content analysis.

Results

A total of 28 practitioners and staff (13 men [46%]; 11 [39%] aged 41-50 years), including medical clinicians, therapists, and other administrative staff, were interviewed. Participants included 17 physicians (61%), 7 therapists (25%), 1 advanced practice practitioner (4%), 1 administrator (4%), and 2 other staff (8%). Twenty-four participants (86%) had at least 5 years of experience treating OUD, and all clinicians had obtained a DATA-2000 waiver, also called an X-waiver, to prescribe buprenorphine. Participants viewed the X-waiver as a symbolic barrier, but identified policy factors like insurance coverage, reimbursement rates, payer policies, and licensure requirements as key variables influencing clinical practice. Clinics relied on supplemental funding to sustain care for uninsured patients. Participants reported that payer-imposed requirements, such as prior authorizations and rigid attendance-based reimbursement, undermined timely access and individualized care and that regulatory frameworks often conflicted with harm reduction principles and created staffing and documentation burdens. Conclusions and Relevance This qualitative study of clinicians and staff in buprenorphine treatment programs found that broader policy and payment reforms could help support low-barrier buprenorphine treatment. Enhancing reimbursement, reducing administrative burdens, and aligning licensure and payer policies with evidence-based practices may improve access and retention. These findings offer actionable insights for policymakers, payers, and health systems seeking to address persistent gaps in OUD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersOpiate Substitution TreatmentPractice Patterns, Physicians'Health Services AccessibilityHealth PolicyHumansAdultFemaleMiddle AgedMalePhiladelphiaQualitative Research

Substanzen

Buprenorphine

Autor:innen und Institutionen

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
  • University of Pennsylvania Center for Addiction Medicine and Policy, Philadelphia.
  • Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania.
  • University of Pennsylvania School of Nursing, Philadelphia.
  • Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania.

Zitieren

APA

Lowenstein, M., Holliday Davis, M., Suhail-Sindhu, S., McMurtrie, G., Grande, D., Hinckley, J., & Aronowitz, S. V. (2026). Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment. JAMA Network Open, 9(6), e2618878. https://doi.org/10.1001/jamanetworkopen.2026.18878

Vancouver

Lowenstein M, Holliday Davis M, Suhail-Sindhu S, McMurtrie G, Grande D, Hinckley J, et al. Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment. JAMA Network Open. 2026;9(6):e2618878. doi:10.1001/jamanetworkopen.2026.18878

BibTeX
@article{Lowenstein2026,
  author = {Lowenstein, Margaret and Holliday Davis, M and Suhail-Sindhu, Selena and McMurtrie, Gary and Grande, David and Hinckley, Julia and Aronowitz, Shoshana V},
  title = {Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {6},
  pages = {e2618878},
  doi = {10.1001/jamanetworkopen.2026.18878}
}
Kostenlos starten →